Ibio Inc Stock News

- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics -

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharmi

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , today announced a research collaboration with the University of Texas Southwestern Medical Center ("UT Southwestern") to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program. Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts ("CAFs") are one of the most abundant and critical components of tumor tissue, which provide physical support for tumor cells and can promote or retard tumorigenesis in a context-dependent manner. CAFs are also involved in the modulation of many components of the immune system, and recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy. 1 In addition, CAF response to chemotherapy is highly variable. 2 Through a series of planned in vitro and in vivo studies, the collaboration will evaluate the potential of the anti-fibrotic effects of iBio''s endostatin E4 molecule to improve the efficacy of concomitant treatments, such as chemotherapy and immunotherapy, in cancer models with a fibrotic component.

iBio will be reporting Q1 earnings on November 15. Wall Street analysts expect iBio will be reporting losses per share of $0.050. Go here to track iBio stock price in real-time ahead of earnings. On November 15, iBio will

BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based

Looking for penny stocks to buy with high-momentum right now? Check these three out for your list The post Hot Penny Stocks to Watch That You Might've Missed This Week appeared first on Penny Stocks t

Pre-clinical successes lead to exclusive licensing agreements for iBio.

iBio, Inc. (IBIO) CEO Thomas Isett on Q4 Fiscal 2021 Results - Earnings Call Transcript

Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-base

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-base

Meme stocks have enjoyed another recent surge. However, don't get caught holding the bag with these seven less promising ones.

BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-base

Industry veteran adds deep expertise in immuno-oncology to the Board Industry veteran adds deep expertise in immuno-oncology to the Board